MedTrace Logo

Teriflunomide Observational Effectiveness Study

NCT02490982 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2021-08-18

No results posted yet for this study

Summary

The main goal of this investigator-initiated study is to evaluate the effectiveness and efficacy of Teriflunomide in a population of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated in regular practice, over a period of at least two years, in the regular setting of a Multiple Sclerosis Clinic.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Teriflunomide

The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Montreal Neurological Institute and Hospital

    collaborator OTHER

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Principal Investigators

  • Pierre Duquette, MD · Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-12-31
Completion
2021-06-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02490982 on ClinicalTrials.gov